Abstract
sFIDA is a platform technology for specific and sensitive quantitation of single proteinaceous particles, such as amyloid-β oligomers as an early biomarker for Alzheimer’s disease (AD). Automation improves robustness and performance of the sFIDA technology, which is a prerequisite for high-throughput measurements and future application of the technology in routine AD diagnostics and other applications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
